

PUBLICATIONS in peer-reviewed journals

Lanzenberger Rupert, MD PD

cIF 178.64, 45 papers, h-index = 11; 382 citations

version July 2010

First or Senior[#] Author (accumulated IF: **51.77**; 13 papers; mean IF: 3.98)
([#] project funding by corresponding and senior author R. Lanzenberger)

1. **Lanzenberger R**, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J. Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder. *Biological Psychiatry* 2007 May 1;61(9):1081-9. Epub 2006 Sep 18. [2009, IF: 8.926]
2. Gerstl F, Windischberger C, Mitterhauser M, Wadsak W, Holik A, Kletter K, Moser E, Kasper S, **Lanzenberger R**. Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. *NeuroImage* 2008 Jun;41(2):204-11. Epub 2008 Mar 6. [2009, IF: 5.739][#]
3. Fink M, Wadsak W, Savli M, Stein P, Moser U, Hahn A, Mien LK, Kletter K, Mitterhauser M, Kasper S, **Lanzenberger R**. Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. *NeuroImage* 2009 Apr 1;45(2):598-605. Epub 2008 Dec 9. [2009, IF: 5.739][#]
4. Witte A. Veronica, Savli M, Holik A, Kasper S, **Lanzenberger R**. Regional sex differences in grey matter volume are associated with sex hormones in the young adult human brain. *NeuroImage* 2010 Jan 15;49(2):1205-1212. Epub 2009 Sep 28. [2009, IF: 5.739].
5. Witte AV, Flöel A, Stein P, Savli M, Mien LK, Wadsak W, Spindelegger C, Moser U, Fink M, Hahn A, Mitterhauser M, Kletter K, Kasper S, **Lanzenberger R**. Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects. *Human Brain Mapping* 2009 Aug;30(8): 2558-70. Epub 2008 Dec 11. [2009, IF 6.256][#]
6. Stein P, Savli M, Wadsak W, Mitterhauser M, Fink M, Spindelegger C, Mien LK, Moser U, Dudczak R, Kletter K, Kasper S, **Lanzenberger R**. The serotonin-1A receptor distribution in healthy men and women measured by PET and [*carbonyl*-¹¹C]WAY-100635. *European Journal of Nuclear Medicine and Molecular Imaging* (Eur J Nucl Med Mol Imaging) 2008 Dec;35(12):2159-68. Epub 2008 Jun 10. [2009, IF 4.531][#]
7. **Lanzenberger R**, Wadsak W, Spindelegger C, Mitterhauser M, Akimova E, Mien LK, Fink M, Moser U, Savli M, Kranz SG, Hahn A, Kletter K, Kasper S. Cortisol plasma levels in Social Anxiety Disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. *International Journal of Neuropsychopharmacology* 2010 Jun 2:1-15. [Epub] [2009, IF: 4.874]
8. Kranz GS, Kasper S, **Lanzenberger R**. Reward and the Serotonergic System *Neuroscience* 2010 Apr 14;166(4):1023-1035. Epub 2010 Jan 28. [2009, IF: 3.292];
9. **Lanzenberger R**, Beisteiner R, Prayer D. Discussion of the Brain Atlas for Functional Imaging (BAFI), W.L. Nowinski, A. Thirunavuukarasuu, D.N. Kennedy; Thieme Verlag, Stuttgart, 2000 *European Journal of Radiology* 2002 Mar;41(3):255-6. [2009, IF: 2,645]

10. Moser U, Wadsak W, Spindelegger C, Mitterhauser M, Mien LK, Bieglmayer C, Kletter K, Kasper S, **Lanzenberger R**. Hypothalamic serotonin-1A receptor binding measured by PET predicts the plasma level of dehydroepiandrosterone sulphate in healthy women. *Neuroscience Letters* 2010 Jun 7;476(3):161-5. Epub 2010 Apr 22. [2009, IF: 1.925]
11. **Lanzenberger R**, Wiest G, Geissler A, Barth M, Ringl H, Wöber C, Gartus A, Baumgartner C, Beisteiner R. fMRI reveals functional cortex in a case of inconclusive Wada testing. *Clinical Neurology and Neurosurgery* 2005 Feb; 107(2):147-51 [2009, IF: 1.303]
12. **Lanzenberger R**, Kasper S. Neuroimaging bei schizophrenen Erkrankungen [Neuroimaging in Schizophrenia]. (REVIEW) *Fortschr Neurol Psychiatr.* 2005 Nov;73 Suppl 1:51-9 [2009, IF: 0.804]
13. **Lanzenberger R**, Hackhofer S, Kranz GS, Kasper S. Wie viel Gehirn braucht der Affekt? Bildgebende Verfahren und affektive Symptome bei Schizophrenie. (REVIEW) *Psychiatrie & Psychotherapie* 2009; Sonderheft Grazer Psychosentage 2007 [2009, IF: 0]; in press

Co-author (accumulated IF: 126.87; 32 papers, mean IF: 3.96; descending order by IF)

1. Spindelegger C*, **Lanzenberger R***, Wadsak W, Mien LK, Stein P, Mitterhauser M, Moser U, Holik A, Pezawas L, Kletter K, Kasper S. (***contributed equally**) Influence of escitalopram treatment on 5-HT_{1A} receptor binding in limbic regions in patients with anxiety disorders. *Molecular Psychiatry* 2009 Nov;14(11):1040-50. Epub 2008 Mar 25 [2009, IF: 15.049]
2. Akimova E, **Lanzenberger R**, Kasper S. The Serotonin-1A receptor in Anxiety disorders. (REVIEW) *Biological Psychiatry* 2009 Oct 1;66(7):627-35. Epub 2009 May 7. [2009, IF: 8.926]
3. Bauer M, Langer O, Dal-Bianco P, Karch R, Brunner M, Abraham A, **Lanzenberger R**, Hofmann A, Joukhadar C, Carminati P, Ghirardi O, Piovesan P, Forloni G, Corrado M, Lods N, Dudczak R, Auff E, Kletter K, Müller M. A positron emission tomography microdosing study with a potential anti-amyloid drug in healthy volunteers and patients with Alzheimer's disease. *Clinical Pharmacology and Therapeutics* 2006 Sep;80(3):216-27. [2009, IF: 6.961]
4. Riederer F, **Lanzenberger R**, Kaya M, Prayer D, Serles W, Baumgartner C. Network atrophy in temporal lobe epilepsy – A voxel-based morphometry study. *Neurology* 2008 Aug 5;71(6):419-25. [2009, IF: 8.172]
5. Windischberger C*, **Lanzenberger R***, Stein P, Holik A, Spindelegger C, Moser U, Gerstl F, Fink M, Moser E, Kasper S. (*contributed equally) Escitalopram attenuates amygdala reactivity to emotional processing as revealed by pharmacological fMRI at 3T. *NeuroImage* 2010;49(2):1161-1170. Epub 2009 Oct 13 [2009, IF: 5.739]; *equally contributed;
6. Weissenbacher A, Kasess C, Gerstl F, **Lanzenberger R**, Moser E, Windischberger C. Correlations and Anticorrelations in Resting-State Functional Connectivity MRI: A Quantitative Comparison of Preprocessing Strategies. *NeuroImage* 2009 Oct 1; 47(4):1408-1416. Epub 2009 May 13. [2009, IF: 5.739]
7. Kasess C, Windischberger C, Cunnington R, **Lanzenberger R**, Pezawas L, Moser E. The suppressive influence of SMA on M1 in motor imagery revealed by fMRI and dynamic causal modeling.

NeuroImage 2008 Apr 1;40(2):828-37. Epub 2007 Dec 8. [2009, IF: 5.739]

8. Beisteiner R, Windischberger W, **Lanzenberger** R, Edward V, Cunnington R, Erdler M, Gartus A, Streibl B, Moser E, Deecke L.
Finger Somatotopy in Human Motor Cortex
NeuroImage. 2001 Jun; 13(6): 1016-26 [2009, IF: 5.739]
9. Geissler A, **Lanzenberger** R, Barth M, Tahamtan A, Milakara D, Gartus A, Beisteiner, R.
Influence of fMRI smoothing procedures on replicability of fine scale motor localization.
NeuroImage 2005 Jan 15; 24(2): 323-31 [2009, IF: 5.739]
10. Edward V, Windischberger C, Cunnington R, Erdler M, **Lanzenberger** R, Mayer D, Endl W, Beisteiner R.
Quantification of fMRI artifact reduction by a novel plaster cast head holder.
Human Brain Mapping 2000 Nov;11(3):207-13. [2009, IF 6.256]
11. Roessler K, Donat M, **Lanzenberger** R, Novak K, Geissler A, Gartus A, Tahamtan AR, Milakara D, Czech T, Barth M, Knosp E, Beisteiner R.
Evaluation of preoperative high magnetic field motor functional MRI (3 Tesla) in glioma patients by navigated electrocortical stimulation and postoperative outcome
J Neurol Neurosurg Psychiatry 2005 Aug;76(8):1152-7 [2009, IF: 4.869]
12. Sacher J, Asenbaum S, Klein N, Geiss-Granadia T, Mossaheb N, Poetzi C, Attarbaschi T, **Lanzenberger** R, Spindelegger C, Rabas A, Heinze G, Dudczak R, Kasper S, Tauscher J.
Binding kinetics of ¹²³I[ADAM] in healthy controls: a selective SERT radioligand.
Int J Neuropsychopharmacol. 2007 Apr; 10(2): 211-8 [2009, IF: 4.874]
13. Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, **Lanzenberger** R, Pötzi C, Holik A, Spindelegger C, Asenbaum S, Dudczak R, Tauscher J, Kasper S.
In vivo imaging of serotonin transporter occupancy by means of SPECT and [¹²³I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.
Psychopharmacology (Berl). 2006 Oct;188(3):263-72; [2009, IF: 4.103]
14. Klein N, Sacher J, Geiss-Granadia T, Mossaheb N, Attarbaschi T, **Lanzenberger** R, Spindelegger C, Holik A, Asenbaum S, Dudczak R, Tauscher J, Kasper S.
Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [¹²³I]ADAM SPECT study.
Psychopharmacology (Berl). 2007 Apr; 191(2): 333-9 [2009, IF4.103]
15. Attarbaschi T, Sacher J, Geiss-Granadia T, Klein N, Mossaheb N, **Lanzenberger** R, Asenbaum S, Dudczak R, Kasper S, Tauscher J.
Striatal D₂ receptor occupancy in bipolar patients treated with olanzapine.
European Neuropsychopharmacology 2007 Jan 15; 17(2):102-7. [2009, IF: 3.684]
16. Beisteiner R, Gartus A, Erdler M, Mayer D, **Lanzenberger** R, Deecke L.
Magnetoencephalography indicates finger motor somatotopy.
Eur J Neurosci. 2004 Jan; 19(2): 465-72. [2009, IF: 3.418]
17. Kasper S, Sacher J, Klein N, Mossaheb N, Attarbaschi-Steiner T, **Lanzenberger** R, Spindelegger C, Asenbaum S, Holik A, Dudczak R.
Differences in the dynamics of SERT occupancy may explain superior clinical efficacy of escitalopram versus citalopram.
Int Clin Psychopharmacol. 2009 May;24(3):119-25 [2009, IF: 3.345]
18. Mitterhauser M, Toegel S, Wadsak W, **Lanzenberger** R, Mien LK, Kuntner C, Wanek T, Harald Eidherr H, Ettliger DE, Viernstein H, Kluger R, Dudczak R, Kletter K
Pre vivo, ex vivo and in vivo evaluations of [⁶⁸Ga]-EDTMP.
Nuclear Medicine and Biology 2007 May; 34(4):391-97 [2009, IF 2.456]
19. Wadsak W, Mien LK, Shanab K, Ettliger DE, Haeusler D, Sindelar K, **Lanzenberger** R, Spreitzer H, Viernstein H, Keppler BK, Dudczak R, Kletter K, Mitterhauser M.

- Preparation and first evaluation of [¹⁸F]FE@SUPPY: a new PET tracer for the adenosine A₃ receptor.
Nuclear Medicine and Biology 2008 Jan; 35(1): 61-6 [2009, IF 2.456]
20. Haeusler D, Nics L, Mien LK, Ungersboeck J, **Lanzenberger** R, Shanab K, Sindelar KM, Viernstein H, Wagner KH, Dudczak R, Kletter K, Wadsak W, Mitterhauser M.
[¹⁸F]FE@SUPPY and [¹⁸F]FE@SUPPY:2 - Metabolic considerations
Nuclear Medicine and Biology 2010 May;37(4):421-6. Epub 2010 Mar 6 [2009, IF: 2.456]
 21. Beisteiner R, **Lanzenberger** R, Novak K, Edward V, Windischberger C, Erdler M, Cunningham R, Gartus A, Streibl B, Moser E, Czech T, Deecke L.
Improvement of presurgical patient evaluation by generation of functional MR risk maps.
Neurosci Lett. 2000 Aug 18;290(1):13-6. [2009, IF: 1.925]
 22. Erdler M, Windischberger C, **Lanzenberger** R, Edward V, Gartus A, Deecke L, Beisteiner R.
Dissociation of supplementary motor area and primary motor cortex in human subjects when comparing index and little finger movements with functional magnetic resonance imaging.
Neurosci Lett. 2001 Nov 2;313(1-2):5-8. [2009, IF: 1.925]
 23. Windischberger W, Cunningham R, Lamm C, **Lanzenberger** R, Langenberger H, Deecke L, Bauer H, Moser E.
Time-resolved Analysis of fMRI signal changes using Brain Activation Movies
Journal of Neuroscience Methods 2008 Mar 30; 169(1): 222-30 [2009, IF: 2.295]
 24. Schöpf V, Kasess CH, **Lanzenberger** R, Fischmeister F, Windischberger C, Moser E.
Fully Explorative Network ICA (FENICA) on resting-state fMRI data.
Journal of Neuroscience Methods 2010 [2009, IF: 2.295]; in press
 25. Schoepf V, Windischberger C, Kasess CH, **Lanzenberger** R, Moser E.
Group ICA analysis of resting-state data: a comparison.
MAGMA (Magnetic Resonance Materials in Physics, Biology and Medicine) 2010 Jun 3 Epub [2009, IF: 1.859]
 26. Haeusler D, Mien LK, Nics L, Ungersboeck J, Philippe C, **Lanzenberger** R, Kletter K, Dudczak R, Mitterhauser M, Wadsak W.
Simple and rapid preparation of [¹¹C]DASB with high quality and reliability for routine applications.
Applied Radiation and Isotopes 2009 Sep;67(9):1654-60. Epub 2009 Mar 20. [2009, IF 1.094]
 27. Haeusler D, Mitterhauser M, Mien LK, Shanab K, **Lanzenberger** R, Schirmer E, Ungersboeck J, Nics L, Spreitzer H, Viernstein H, Dudczak R, Kletter K, Wadsak W.
Radiosynthesis of a novel potential adenosine A₃ receptor ligand, 5-ethyl 2,4-diethyl-3-((2-[¹⁸F]fluoroethyl)sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([¹⁸F]FE@SUPPY:2).
Radiochimica Acta 2009; 97: 753-8 [2009, IF 1.459]
 28. Wadsak W, Mien LK, Ettliger DE, **Lanzenberger** R, Haeusler D, Dudczak R, Kletter K, Mitterhauser M.
Simple and fully automated preparation of [carbonyl-11C]WAY-100635.
Radiochimica Acta 2007, 95, 417-22 [2009, IF: 1.459]
 29. Wadsak W, Mien LK, Ettliger DE, Feitscher S, **Lanzenberger** R, Marton J, Dudczak R, Kletter K, Mitterhauser M.
Preparation and radiosynthesis of [¹⁸F]FE@CFN (2-[¹⁸F]fluoroethyl 4-[N-(1-oxopropyl)-N-phenylamino]-1-(2-phenylethyl)-4-piperidinecarboxylate): a potential μ-opioid receptor imaging agent.
Radiochimica Acta 2007, 95, 33-8 [2009, IF 1.459]
 30. Robinson S, Hoheisel B, Windischberger C, Habel U, **Lanzenberger** R, Moser E
fMRI of the Emotions: Towards an Improved Understanding of Amygdala Function.
Current Medical Image Review 2005; Vol. 1(2): 115-129, [2009, IF 0.574]
 31. Mitterhauser M, Haeusler D, Mien LK, Ungersboeck J, Nics L, **Lanzenberger** R, Sindelar K, Viernstein H, Dudczak R, Kletter K, Wadsak W.

Automatisation and first evaluation of [¹⁸F]FE@SUPPY:2, an alternative PET-Tracer for the Adenosine A₃ Receptor: A Comparison with [¹⁸F]FE@SUPPY.

The Open Nuclear Medicine Journal (TONMEDJ) 2009;1:15-23 [2009, IF: 0];

32. Fink M, Akimova E, Spindelegger C, Hahn A, **Lanzenberger** R, Kasper S.
Social Anxiety Disorder: Epidemiology, Biology and Treatment
Psychiatria Danubina 2009 Dec;21(4):533-42 [2009, IF: 0; MEDLINE listed]

BOOK CHAPTERS

1. Kasper S, Akimova E, Fink M, **Lanzenberger** R (2009)
Maintenance pharmacotherapy in schizophrenia.
In: Kasper S, Papadimitriou G (eds.) Schizophrenia. 2nd edition.
London: Informa Healthcare, pp. 174-184